Clarium Capital Management
Clarium Capital Management is a global macro hedge fund managed by Peter A. Thiel. The firm invests in the public equity, fixed income, and hedging markets across the globe primarily investing in the stocks of micro-cap companies, distressed debt, commodities, bonds, currencies, and private investments employing an opportunistic approach. Clarium Capital Management was founded in 1998 and is based in San Francisco, CA.
View Older Stories View More Recent Stories
-
Trade Republic Launches Stock Gifting, Ahead of the Christmas Season, to Allow Trade Republic Users to Support Their Family and Friends on Their Savings Journeys
-
MoneyHero Group to Announce Third Quarter 2024 Results
-
Lindus Health Rolls Out "All-in-One Infectious Disease CRO" Bespoke to Clinical Trials for Infectious Disease Interventions
-
Former Team USA Chief Joins Enhanced Games, Among Other Senior Hires Ahead Of 2025 Debut
-
New Study from Lindus Health Finds Patients are More Likely to Join a Clinical Trial with Telehealth Care
-
Thousands of election gamblers anticipate betting jackpot after Trump win
-
How Trump's second administration affects business: Musk, tariffs and more
-
Citrea Raises $14M to Expand Bitcoin Beyond Digital Gold
-
Lindus Health Introduces Its "All-in-One Women's Health CRO" for Clinical Trials in the Women's Health Space
-
Thiel's Palantir dumped by Norwegian investor over work for Israel
-
MoneyHero Appoints Distinguished Global Executive Wallace Pai to Board of Directors
-
New Pharmanovia Study Results Reveal Chloral Hydrate Noticeably Improves Severe Insomnia Within Two Weeks
-
AI hiring platform Mercor backed by Dorsey, Peter Thiel in $30 million fundraise
-
Mercor Raises $30M Series A at a $250M Valuation to Create Jobs with AI
-
MoneyHero Group Reports Second Quarter 2024 Results
-
Lindus Health Launches "All-in-One Ophthalmology CRO" Tailored to Clinical Trials in Ophthalmology
-
MoneyHero Group to Announce Second Quarter 2024 Results
-
JD Vance Urges Peter Thiel to Help Bankroll Trump Campaign - FT
-
Lindus Health Announces the Completion of Two Clinical Trials for Woebot Health's Digital Application for Depression and Anxiety Symptoms
-
Tech donor network co-founded by JD Vance seeks to push America to the right
-
Palantir to deploy AI products on Microsoft Azure for U.S. government agencies
-
Lindus Health Unveils "All-in-One Dermatology CRO" Offering for Dermatology Clinical Trials
-
Palantir raises annual forecasts on GenAI strength; shares surge
-
The Revealing Economics of Psychedelics
-
Morris Industries Invests in Series B Round of Strive Enterprises
-
STRIVE RAISES $30 MILLION IN SERIES B FUNDING ROUND
-
Neuralink's value jump leaves some Musk employees itching to cash out
-
BANKRUPTCY TRUSTEE JOINS DEBT HOLDERS OF GLORIFI TO PURSUE ALLEGED SABOTEURS
-
With Trump VP pick J.D. Vance, Silicon Valley conservatives land a 'tech bro' on the ticket
-
Elon Musk endorses Trump in presidential race, calls him "tough"
-
Lindus Health and Aktiia to launch observational clinical trial for Aktiia's Optical Blood Pressure Monitoring Device
-
ValueZone Empowers Traders with Key Strategies Amidst Bitcoin Price Drop
-
MoneyHero Group Announces Strategic Partnership with Jirnexu Pte. Ltd in Malaysian Market
-
Lindus Health Launches Bespoke "All-in-One Medical Device CRO" Offering for Medical Device Clinical Trials
-
MoneyHero Group Appoints Accomplished Legal and Finance Executive Steve Teichman as Board Director
-
AI startup Etched raises $120 million to develop specialized chip
-
MoneyHero Group Reports First Quarter 2024 Results
-
Maxterial Raises nearly $8 Million in Series A Funding
-
MoneyHero Group to Announce First Quarter 2024 Results
-
Trump rakes in $12 million at tech fundraiser in liberal San Francisco
-
Responsive Launches Advisory Board with Leaders from Microsoft, DocuSign, The Revenue Enablement Institute and Stanford University
-
Lindus Health Introduces "All-in-One Consumer Health CRO" Offering Tailored to Clinical Trials for Consumer Health Products
-
Integro Bank Announces Special Guest Speaker Jack Selby for May's CEO Club Event
-
Lindus Health Announces Cosmetics Clinical Trial with Acinonyx Bio to Evaluate an Alternative to Benzoyl Peroxide for Inflammatory Acne
-
MoneyHero Appoints Hao Qian Chief Financial Officer
-
MoneyHero Appoints New Group Heads of Marketing and Operations
-
Dr. Tim Garnett, Former Chief Medical Officer of Eli Lilly, Joins Lindus Health's Advisory Board
-
Palantir raises 2024 forecast on robust AI demand, but falls short of lofty expectations
-
Lindus Health and University of Oxford Publish Study Citing Key Strategies to Foster Diversity in Clinical Trial Participation
-
MoneyHero Group Reports Fourth Quarter and Full Year 2023 Results

